NRSNW · NeuroSense Therapeutics Ltd.

Summary

NeuroSense Therapeutics Ltd. announced the rescheduling of its pre-NDS meeting with Health Canada to May 2026 to incorporate additional clinical, biomarker, and survival data for PrimeC, while expecting Alzheimer’s study results in coming weeks. This strengthens the regulatory foundation and positions the company ahead of 2026 value inflection points in ALS and Alzheimer’s programs.

Key takeaways

• Pre-NDS meeting with Health Canada rescheduled to May 2026
• Inclusion of additional emerging clinical, biomarker, and survival data in briefing package
• Alzheimer’s Disease study clinical and biomarker results expected in coming weeks
• Statistically significant 65% reduction in risk of death for PrimeC
• FDA clearance to initiate pivotal Phase 3 PARAGON trial in ALS
• Advancing PrimeC under NOC/c pathway in Canada